Every 424B that ALLURION TECHNOLOGIES INC (ALUR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ALUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALUR filings page.
Allurion Technologies, Inc. has registered 5,988,024 shares of common stock for potential resale by existing securityholders. The shares include 2,994,012 shares issued in a November 2025 private placement and 2,994,012 shares issuable upon exercise of accompanying warrants with a $1.67 exercise price. The company will not receive proceeds from any resale of these shares but could receive up to approximately $5.0 million if all November 2025 warrants are exercised for cash. As of January 5, 2026, 12,279,181 shares of common stock were outstanding. The prospectus notes that large or sustained resales could put pressure on the stock price. Allurion remains an emerging growth and smaller reporting company and highlights recent financing steps and an exchange agreement with RTW tied to Series B preferred stock and specified performance conditions.
Allurion Technologies, Inc. has filed a prospectus supplement updating its Form S-1 registration statement covering up to 65,211,325 shares of common stock. The supplement incorporates a recent current report that details the results of the company’s 2025 annual meeting of stockholders held on December 18, 2025, where seven proposals were presented for a vote. The company notes there were sufficient votes to approve Proposals 3 through 7, so a contingent proposal to adjourn the meeting for additional solicitation was not needed. Allurion’s common stock trades on the NYSE under the symbol ALUR, which last closed at $1.47 per share on December 19, 2025, while its public warrants closed at $0.02 per warrant.
Allurion Technologies, Inc. has a prospectus supplement covering up to 56,548,268 shares of common stock, updating its existing S-1/A prospectus with information from a recent Form 8-K. The update attaches the report on the company’s 2025 Annual Meeting of Stockholders held on December 18, 2025, where seven proposals were considered and approved without needing an adjournment. Stockholders elected directors including Omar Ishrak, M.D., Douglas Hudson, and R. Jason Richey, with several other proposals receiving strong support based on the reported vote totals.
The company’s common stock trades on the NYSE under the symbol ALUR, and its public warrants trade under ALUR.WS. On December 19, 2025, the common stock last traded at $1.47 per share and the public warrants at $0.02 per warrant. Allurion is classified as an emerging growth company, which allows it to follow reduced public reporting requirements, and it reminds investors to review the risk factors in the base prospectus before investing.
Allurion Technologies, Inc. has an effective prospectus covering the resale of up to 65,211,325 shares of common stock, and this supplement adds details from a new current report. The company agreed to a $5 million private placement of 2,994,012 common shares and accompanying warrants at $1.67 per share and warrant, with the warrants exercisable after stockholder approval of the underlying shares, which the company must seek by January 31, 2026.
Allurion also signed an exchange agreement with RTW to swap all amounts outstanding under certain convertible notes and two revenue interest financing agreements for newly created Series B convertible preferred stock with a stated value of $1,000 per share, an 8.25% annual dividend, and a conversion price of $3.37 per share, subject to a 9.9% ownership cap. The Series B ranks senior to common stock, carries voting and board nomination rights tied to RTW’s ownership and covenant compliance, and requires the company to maintain at least $3 million in unrestricted cash and obtain FDA marketing authorization for a product by December 31, 2026. Separately, RTW recently converted about $5 million of notes into 1,492,539 common shares at $3.35 per share.